Valuation : Caplin Point Laboratories Limited

Market Cap 19TCr 202.6Cr 173.89Cr 163.21Cr 149.07Cr 281.33Cr 282.68Cr 1.93TCr 748.53Cr 9.75TCr 760.69Cr 744.18Cr 32TCr P/E 2026
17.9x
P/E 2027 * 26.3x
Enterprise Value 19TCr 202.6Cr 173.89Cr 163.21Cr 149.07Cr 281.33Cr 282.68Cr 1.93TCr 748.53Cr 9.75TCr 760.69Cr 744.18Cr 32TCr EV / Sales 2026
5.23x
EV / Sales 2027 * 7.71x
Free-Float
26.56%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day+0.97%
1 week-1.18%
Current month+0.95%
1 month-3.08%
3 months+24.80%
6 months+46.98%
Current year+38.22%
1 week 2,459.8
Extreme 2459.8
2,600
1 month 2,382.5
Extreme 2382.5
2,675
Current year 1,500.3
Extreme 1500.3
2,699
1 year 1,500.3
Extreme 1500.3
2,699
3 years 954
Extreme 954
2,699
5 years 575
Extreme 575
2,699
10 years 176.2
Extreme 176.2
2,699
Manager TitleAgeSince
Chief Executive Officer 71 28/03/2015
Director of Finance/CFO - 19/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 27/01/2010
Director/Board Member - 05/11/2025
Director/Board Member 71 28/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%-1.18% - - 200.75Cr
+0.73%+0.70%+19.56%+71.29% 4.78TCr
-0.37%+1.04%+54.31%+121.86% 4.03TCr
+1.23%-0.14%-10.12%+15.55% 1.19TCr
+3.41%+7.67%+20.38%+87.48% 1.2TCr
+0.19%0.00%+30.98%+150.00% 924.22Cr
+0.45%+3.73%+25.09%+46.01% 782.51Cr
-1.41%-0.16%+52.26%-11.99% 734.47Cr
+0.89%+9.50%+26.11%+220.67% 721.43Cr
+0.95%-8.22%-39.88%+16.67% 527.97Cr
Average +0.70%+1.34%+19.86%+79.73% 1.65TCr
Weighted average by Cap. +0.56%+1.06%+27.49%+86.59%

Financials

2026 2027 *
Net sales 2.13TCr 22Cr 19Cr 18Cr 16Cr 31Cr 31Cr 212.7Cr 82Cr 1.07TCr 84Cr 82Cr 3.56TCr 2.51TCr 26Cr 23Cr 21Cr 19Cr 37Cr 37Cr 250.62Cr 97Cr 1.26TCr 99Cr 97Cr 4.19TCr
Net income 616.2Cr 6.46Cr 5.55Cr 5.2Cr 4.75Cr 8.97Cr 9.01Cr 62Cr 24Cr 310.87Cr 24Cr 24Cr 1.03TCr 726.45Cr 7.62Cr 6.54Cr 6.14Cr 5.6Cr 11Cr 11Cr 73Cr 28Cr 366.49Cr 29Cr 28Cr 1.21TCr
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
27/26/27 2,540.70 +0.97% 40,296
26/26/26 ₹2,516.30 +1.80% 59,944
25/26/25 ₹2,471.80 -0.97% 50,538
24/26/24 ₹2,496.10 -2.53% 2,10,240
21/26/21 ₹2,560.80 +1.23% 49,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,542.15INR
Average target price
2,765.00INR
Spread / Average Target
+8.77%

Quarterly revenue - Rate of surprise